What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.
暂无分享,去创建一个
Neil Woodford | N. Woodford | D. Livermore | M. Warner | M. Doumith | S. Mushtaq | Michel Doumith | David M Livermore | Marina Warner | Shazad Mushtaq | Jiancheng Zhang | Jiancheng Zhang
[1] D. Sofianou,et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin. , 2010, The Journal of hospital infection.
[2] D. Paterson,et al. Activity of Temocillin against KPC-Producing Klebsiella pneumoniae and Escherichia coli , 2009, Antimicrobial Agents and Chemotherapy.
[3] N Woodford,et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. , 2011, The Journal of antimicrobial chemotherapy.
[4] I. Damjanova,et al. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary , 2010, European Journal of Clinical Microbiology & Infectious Diseases.
[5] P. Nordmann,et al. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. , 2009, The Lancet. Infectious diseases.
[6] H. Bonatti. Tigecycline for Treatment of Pneumonia and Empyema Caused by Carbapenemase-Producing Klebsiella pneumoniae , 2008 .
[7] N. Woodford,et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study , 2010, The Lancet. Infectious diseases.
[8] M. Falagas,et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. , 2010, The Lancet. Infectious diseases.
[9] A. Vatopoulos. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece--a review of the current evidence. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[10] J. Turnidge,et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. , 2006, The Lancet. Infectious diseases.
[11] H. Nikaido,et al. Porin channels in Escherichia coli: studies with beta-lactams in intact cells , 1983, Journal of bacteriology.
[12] Y. Chuang,et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. , 2010, Diagnostic microbiology and infectious disease.
[13] C. Nicolaou,et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. , 2009, The Journal of infection.
[14] N. Woodford,et al. Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae , 2010, Antimicrobial Agents and Chemotherapy.
[15] A. Levin,et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] P. Nordmann,et al. Spread of OXA-48-Encoding Plasmid in Turkey and Beyond , 2010, Antimicrobial Agents and Chemotherapy.